

bjc club

PROGRAMMA

28 NOVEMBRE 2014

15:00

Benvenuto e apertura lavori
L. Gianni

15:15

Presentazione e premiazione
Christina Davies
L. Gianni, A. Bottini, L. Dogliotti

15:30

Long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years after diagnosis of oestrogen receptor-positive breast cancer: ATLAS, a randomised trial
R. Gray

16:30

Discussione
PF. Conte

16:45

Presentazione e premiazione
Giampaolo Bianchini
F. Cognetti, G. Mustacchi, S. De Placido

17:00

Proliferation and estrogen signaling can distinguish patients at risk for early versus late relapse among estrogen receptor positive breast cancers
G. Bianchini

18:00

Discussione
P. Pronzato

18:15

Conclusioni
L. Gianni

29 NOVEMBRE 2014

09:00

PRESENTAZIONE LAVORI UNDER 40
MODERATORI: **M. Mottolose, A. Berruti**
DISCUSSANT: **M. Giuliano, M.G. Arpino**

Association of molecular subtypes with Ki-67 changes in untreated breast cancer patients undergoing pre-surgical trials

PRESENTER: **S. Gandini**
S. Gandini, A. Guerrieri Gonzaga, G. Pruneri, D. Serrano, M. Cazzaniga, M. Lazzeroni, P. Veronesi, H. Johansson, B. Bonanni, G. Viale, A. De Censi

Double-Blind, Placebo-Controlled, Multicenter, Randomized, Phase IIB Neoadjuvant Study of Letrozole-Lapatinib in Postmenopausal Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative, Operable Breast Cancer

PRESENTER: **V. Guarneri**
V. Guarneri, D. Generali, A. Frassoldati, F. Artioli, C. Boni, L. Cavanna, E. Tagliafico, A. Maiorana, A. Bottini, K. Cagossi, G. Bisagni, F. Piacentini, G. Ficarra, S. Bettelli,

E. Roncaglia, S. Nuzzo, R. Swaby, C. Ellis, C. Holford, P.F. Conte

Prognostic value of tumor-infiltrating lymphocytes on residual disease after primary chemotherapy for triple-negative breast cancer: a retrospective multicenter study

PRESENTER: **M.V. Dieci**
M.V. Dieci, C. Criscitiello, A. Goubar, G. Viale, P.F. Conte, V. Guarneri, G. Ficarra, M.C. Mathieu, S. Delalogue, G. Curigliano, F. Andre

Incidence of hepatitis in patients with evidence of past or current hepatitis B or C during chemotherapy for early breast cancer

PRESENTER: **A. Levaggi**
A. Levaggi, A. De Maria, B. Dozin, G. Iacono, C. Bighin, S. Giraudi, M. Lambertini, A. D'Alonzo, F. Poggio, P. Pronzato, L. Del Mastro

Prospective neoadjuvant analysis of PET imaging and mechanisms of resistance to Trastuzumab shows role of HIF1 and autophagy

PRESENTER: **D. Generali**
D. Generali, A.L. Harris, F. Ferrozzi, R. Bertoni, G. Ferrero, M. Martinotti, G. Brugnoli, M. Milani, M. Ardine, C. Strina, G. Allevi, L. Zanotti, M.R. Cappelletti, A. Bottini, A. Giatromanolaki, M.I. Koukourakis

10:00

When Nanotechnology meets Oncology in Breast Cancer
MODERATORI: **V. Adamo, M.T. Ionta, A. Sapino**

nab-Paclitaxel: clinical evidence
M. De Laurentis

Clinical development overview
P. Pronzato

NEOADJUVANT SETTING
DISCUSSANT: **R. Bordonaro**

Studio ETNA

Neoadjuvant chemotherapy with nab-paclitaxel in women with HER2-negative high-risk breast cancer - Phase III
M. Zambetti

METASTATIC SETTING:
COMBINATION THERAPY
DISCUSSANT: **L. Del Mastro, F. Puglisi**

11:15

Studio TNACITY
Phase 2/3, multi/center, open/label, randomized study of weekly nab[®]-paclitaxel in combination with gemcitabine or carboplatin, compared to gemcitabine/carboplatin, as first line treatment in subjects with ER, PgR, and HER2 negative (triple negative) metastatic breast cancer
P.F. Conte

Studio GOIM

A multicenter phase II trial of nab-paclitaxel and capecitabine as first line treatment in her-2 negative metastatic breast cancer (mbc)
R. Bordonaro

METASTATIC SETTING:
OPTIMAL DOSE
DISCUSSANT: **A. Frassoldati, C. Marchiò**

Studio EFFECT

A randomized phase II study to evaluate the Efficacy and impact on Function of two different doses of nab-paclitaxel in elderly patients with advanced breast cancer
L. Biganzoli

Studio SNAP

A randomized phase II study evaluating different schedules of nab-Paclitaxel in metastatic breast cancer
F. Puglisi

METASTATIC SETTING
DISCUSSANT: **G. Mustacchi, F. Cognetti**

Studio TACT

A phase II randomized, open-label study evaluating the addition of trastuzumab to (nabTM)-paclitaxel as first line treatment in primary HER2 negative metastatic breast cancer patients with HER2 positive Circulating Tumor Cells (CTCs)
D. Generali

Studio ABRAMYO

Phase I-II study of weekly nab (nanoparticle albumin - bound) paclitaxel (nab-paclitaxel) in combination with liposomal encapsulated doxorubicin (LDox) in patients with HER2 negative metastatic breast cancer
P. Papaldo

Studio GIM 13 - AMBRA

Longitudinal, observational study on the choices of chemotherapy for HER2-negative metastatic breast cancer in the clinical practice
M. Cazzaniga

Activity and safety of albumin-bounded paclitaxel (nab-paclitaxel) in second and further chemotherapy lines for metastatic breast cancer (MBC): a real world clinical practice multicenter italian experience
M. Cazzaniga

Round Table

A. Bottini, F. Cognetti, P. Conte, S. De Placido, L. Dogliotti, L. Gianni, G. Mustacchi, P. Pronzato

13:30

Fine Lavori



bjclub

LOCATION

STARHOTEL ROSA GRAND
Piazza Fontana, 3
20122 Milano

SEGRETERIA ORGANIZZATIVA



OVER Srl
Via Pagliari, 4
26100 Cremona
tel 0372 23310
fax 0372 569605
www.overgroup.eu

ECM

Il corso è stato accreditato per le seguenti discipline:
Oncologia, Radioterapia,
Anatomia Patologica,
Chirurgia Generale, Biologia
ed ha ottenuto 8 crediti E.C.M.

BOARD

Alberto Bottini
Francesco Cognetti
Pierfranco Conte
Sabino De Placido
Luigi Dogliotti
Luca Gianni
Giorgio Mustacchi
Paolo Pronzato

CON IL PATROCINIO DELL'ASSOCIAZIONE ITALIANA DI ONCOLOGIA MEDICA



CON IL CONTRIBUTO INCONDIZIONATO DI



GIAMPAOLO BIANCHINI

OSPITE NAZIONALE

CHRISTINA DAVIES

OSPITE INTERNAZIONALE

LUCA GIANNI

PRESIDENTE DEL CONGRESSO

STARHOTEL ROSA GRAND
PIAZZA FONTANA, 3 - 20122 MILANO



28-29
NOVEMBRE
2014